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Chapter 1: Introduction 
 Depression is one of the most common mental disorders in the United States.1 
Despite many years of research on treatments for depression, it is still unclear as to how 
to successfully treat people so that they achieve remission of depression symptoms. A 
variety of treatments for major depressive disorder (MDD) are currently used, including 
standard pharmaceutical antidepressant medication and complementary and alternative 
medicine (CAM). Response to treatments for MDD varies widely in individuals and 
placebo response rates of approximately 30% are common.2 Such placebo response rates 
can make it difficult to interpret study results and might increase the chance of dismissing 
potentially efficacious treatments.3  
CAM use in the United States has been increasing over the last several decades 
and is particularly prevalent among people with MDD.4 The botanical extract St John’s 
wort (Hypericum perforatum) is popular for the treatment of depression in the U.S. and 
Europe despite inconsistent evidence of its efficacy, especially in treating severe MDD.5 
In the trial by the Hypericum Depression Study Group of St John’s wort for MDD, 
neither the standard antidepressant sertraline nor St John’s wort was more effective than 
placebo.6 These results have raised concerns about placebo-response in studies of CAM 
treatment for MDD.7 Such results, however, might be influenced by participant 
characteristics that could moderate treatment response. In particular, people with certain 
subtypes of depression seem to respond differently to treatment.8 Given the possible 
consequences of not properly treating depression, it is important to elucidate what might 





Since the diagnostic criteria for depression consist of heterogeneous symptoms, 
there might be clinical utility in distinguishing different types of depression such as 
anxious depression or melancholic depression. Melancholic depression is major 
depression with anhedonia, significant weight loss, psychomotor retardation or agitation, 
early morning insomnia, and guilt.9 Anxious depression is major depression with high 
levels of anxiety.10 The main objective of this study was to examine the effect of the 
melancholic and anxious subtypes of major depression on treatment response in the 
Hypericum Depression Trial. The specific aims of this research were as follows. 
Aim 1. To classify the Hypericum Depression Trial population in terms of depression 
subtype. 
Participants were classified as having melancholic versus nonmelancholic depression and 
by having anxious depression versus nonanxious depression. The demographic and 
clinical correlates of each group were then examined. Based on previous studies of 
standard antidepressants in large community samples,10 one hypothesis was that 
participants with melancholic depression would be more likely than those with 
nonmelancholic depression to be male, have greater severity of depression, and a shorter 
duration of the current depressive episode. It was also predicted that participants with 
anxious depression would be more likely than those with nonanxious depression to be 
female, have greater severity of depression, and have more functional impairment.  
Aim 2. To compare treatment response in participants with melancholic depression 
versus nonmelancholic depression. 
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The hypothesis related to this aim was that people with melancholic depression would be 
more likely than those with nonmelancholic depression to respond to treatment with St 
John’s wort or sertraline. Also, people with melancholic depression were predicted to be 
less likely to respond to placebo than those with nonmelancholic depression. 
Aim 3.  To compare treatment response in participants with anxious depression versus 
nonanxious depression. 
The hypothesis corresponding to this aim was that people with anxious depression would 
be less likely than people with nonanxious depression to respond to treatment with St 
John’s wort or sertraline. Additionally, people with anxious depression would be more 
likely than those with nonanxious depression to respond to placebo.  
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Chapter 2: Background 
Overview of Major Depression 
Several kinds of depression are recognized in the widely-used American 
Psychiatric Association’s classification system of diagnostic criteria, including dysthymic 
disorder and major depression.9 The exact cause of MDD is currently unknown but 
genetic, chemical, environmental, psychological, and social factors appear to intersect in 
the etiology of the disease. The American Psychiatric Association, in the most recent 
edition of their Diagnostic and Statistical Manual (DSM-IV), defines major depression as 
the presence of at least five of the following symptoms nearly every day during the same 
2-week period.9   
• depressed mood 
• markedly diminished interest or pleasure in all, or almost all, activities 
• significant weight loss or weight gain or decrease or increase in appetite 
• insomnia or hypersomnia 
• psychomotor agitation or retardation  
• fatigue or loss of energy 
• feelings of worthlessness or excessive or inappropriate guilt 
• diminished ability to think or concentrate, or indecisiveness 
• recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation 
without a specific plan, or a suicide attempt or a specific plan for committing 
suicide 
 
Combinations of these symptoms are considered to occur in episodes. An episode could 
occur only once but episodes usually recur throughout a person’s life.  
Depression is a major public health problem due to its prevalence and its 
association with significant disability, morbidity, and mortality. Depression is a leading 
cause of disease burden throughout the world.11 The symptoms of depression have been 
shown to impair ability to function in work, household, relationship, and social roles in 
more than 50% of people with major depression.12 Major depression is the leading cause 
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of the burden of disease, as measured by disability-adjusted life years, in middle- and 
high-income countries.13 Depression is the fourth largest cause of disability worldwide 
and the largest source of disability for Americans between the ages of 15 and 44 years.14 
Lifetime prevalence for major depression has been estimated to be 15 percent-17 
precent.15 The annual 12-month prevalence of depression in the U.S. is estimated at 6.7 
percent.1  
In 2000, the cost of depression in the United States was estimated to be $83 
billion. This included $26 billion in treatment costs and $57 billion in losses produced by 
absenteeism, reduced productivity, and lifetime earnings lost due to suicide-related 
deaths.16 People with depression have reported an average of 35 days in the past year 
when they were unable to work or carry out their normal activities due to their 
depression.17 In comparison, people with asthma, heart disease, or diabetes reported an 
average of 10.6 days, 8.8 days, and 6.4 days, respectively, when they were unable to 
perform their regular duties. Depression is also associated with increased mortality 
compared to the general population. Suicide-related deaths account for part of this 
increased mortality but it appears that premature mortality might also be related to 
chronic comorbid medical illnesses and social factors.18-20  
Given the burden of major depression for the individual and for society in general, 
effective treatments are important. Antidepressant medication and psychotherapy are the 
most common methods of treatment. Despite the importance and availability of 
treatment, only 51.7% of people with depression receive treatment.21 Of those who 
receive treatment, only 38.0% receive minimally adequate treatment, as defined by at 
least two months of appropriate medication plus at least four visits to a physician or eight 
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sessions of psychotherapy lasting an average of 30 minutes.21 Of those people who do 
receive treatment for major depression, pharmacotherapy is effective for only 
approximately 70%.22 
Even when people with major depression do receive treatment, response to 
treatment can vary widely. Poor response to one treatment does not necessarily mean that 
a different treatment will not be effective.23 Unfortunately, many people do not try 
alternate treatments after the first one fails. Only about half of people make follow-up 
visits after starting antidepressant treatment.24 Because there is usually such a narrow 
window of opportunity to effectively treat major depression, being able to provide 
personalized medicine by knowing the best first treatment for a particular person would 
be highly beneficial.23 Characteristics of individuals with depression that reliably predict 
response to treatment must first be identified in order to develop personalized medicine 
for depression. Numerous characteristics that might moderate treatment response to 
standard antidepressant medication have been studied, including sociodemographic, 
clinical, and biological characteristics. Most studies of possible predictors of response 
have focused on the class of standard antidepressants known as selective serotonin 
reuptake inhibitors (SSRI).25 One possible moderator of treatment response that has been 
considered is subtype of depression. While subtypes of depression have been studied as 
moderators of treatment with standard antidepressant medication.8, 26, 27 there has been 






Treatment for Depression 
Standard Antidepressants 
 Major depression is usually treated with standard antidepressant medications but 
the effect sizes of these antidepressants in bringing about remission of depression 
symptoms have been modest in clinical trials.28, 29 Despite the modest effectiveness, 
standard antidepressants were the fourth-largest pharmaceutical class in terms of sales in 
2009, with sales of $9.9 billion.30 SSRIs or the older tricyclic antidepressants are 
generally the first antidepressants to be tried when treating depression. Standard 
antidepressants are thought to work by affecting the metabolism and receptors of 
neurotransmitters in the brain.31 Antidepressants are generally classified by the receptors 
believed to be involved in the antidepressant’s mechanism of action. Some of the first 
pharmaceutical antidepressants used to treat major depression were monoamine oxidase 
inhibitors (MAOI) and tricyclic antidepressants (TCA).32 MAOIs and TCAs eventually 
dropped out of favor because of their overwhelming side effects and possibly fatal 
contraindications/reactions. These older classes of antidepressants have more recently 
been replaced by selective serotonin reuptake inhibitors (SSRI) such as fluoxetine, 
paroxetine, and sertraline. SSRIs appear to be only partially effective at completely 
ameliorating major depression. The SSRIs now have competition from the serotonin 
norepinephrine reuptake inhibitors (SNRI) such as venlafaxine and duloxetine.  Both 
newer and the older classes of standard antidepressants fall short in terms of inadequate 
efficacy in achieving complete symptom remission and undesirable side effects.33 The 
most commonly prescribed antidepressants that received FDA-approval between 1987 
and 1999 were the SSRIs fluoxetine, paroxetine, and citalopram, the SNRI venlafaxine, 
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and the serotonin norepinephrine dopamine reuptake inhibitor nefazodone.34 It seems that 
SSRIs and SNRIs are both only moderately effective for people with the most severe 
depression.28 In a pooled analysis of trials treating major depression with the SNRI 
venlafaxine, SSRIs or placebo, only 35% of people taking SSRIs experienced complete 
symptom remission.35 Remission rates for placebo were 25%.   
St John’s Wort 
 The National Center for Complementary and Alternative Medicine defines 
complementary and alternative medicine as “a group of diverse medical and health care 
systems, practices, and products that are not presently considered part of conventional 
medicine.”36 Among adults who participated in the National Comorbidity Survey 
Replication and the National Survey on American Life: Coping with Stress in the 21st 
Century, 40% of those with a mood disorder reported using CAM in the previous 12 
months.37 Of those with an anxiety disorder, 35% used at least one form of CAM. Forty 
one percent of those with comorbid mood and anxiety disorders used CAM. Of study 
participants who met criteria for any DSM-IV disorder in the last 12 months and used 
CAM, 26% reported using herbal therapy.  
One popular form of herbal therapy is St John’s wort (Hypericum perforatum) 
supplements.38 In Germany and other countries in Europe, St John’s wort has been used 
for centuries for treating mild to moderate depression.39 The regulation of St John’s wort 
products varies by country and thus the formulations available on the market can differ 
considerably.29 The composition of active ingredients in St John’s wort supplements can 
vary considerably although hyperforin and total hypercerin are thought to be the most 
main components.40 Despite its popularity, the exact nature of the efficacious ingredients 
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and the pharmacological mechanism of the antidepressant effects are relatively 
unknown.39 Differential responses to St John’s wort have been reported for different 
subtypes of depression.41  Side effects of St John’s wort are thought to be mild although 
there is concern over the possibility of herbal-drug interactions in people taking 
medication and supplements in addition to St John’s wort.42  
There is much debate over the efficacy and effectiveness of St John’s wort in 
people with major depression. There is more support for the use of St John’s wort in mild 
to moderate major depression but less support for using it for severe major depression. 
This lack of consensus might be due to heterogeneity in clinical trials methodology and 
inconsistency in which outcome measures are used.29 One multi-site trial of St John’s 
wort versus placebo for moderate to severe major depression found that St John’s wort 
was not more effective than placebo.43 In a trial of treatment with St John’s wort, 
fluoxetine, or placebo for people with mild to moderate depression, St John’s wort was 
significantly more effective than fluoxetine but not more effective than placebo.39 In one 
review of studies of St John’s wort compared with placebo or standard antidepressants 
for the treatment of depression, it was found that St John’s wort was superior to placebo 
and similarly effective as standard antidepressants.29 This same review also concluded 
that fewer side effects were associated with St John’s wort than with standard 
antidepressants and that results of studies in Germany were generally more favorable than 
results from studies in other countries.  
Measuring Treatment Response 
  In studies of treatment for major depression, treatment response is usually defined 
as a certain amount of change in depression severity between baseline and the end of 
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treatment. Severity of depression has been most often measured with the Hamilton 
Depression Rating Scale (HAM-D).44 According to Hamilton, this observer-rated scale is 
a way to assess the initial severity of depression and any changes in the severity. The 
scale should not be used to diagnose depression.45 The HAM-D was originally published 
in 1960 with 17 core items and was intended to systematically quantify results of clinical 
interviews with inpatients that had already been diagnosed with a depressive  
disorder.46, 47 The 17 items assess depressed mood, guilt, suicide, initial insomnia, middle 
insomnia, delayed insomnia, work and interests, psychomotor retardation, psychic 
anxiety, somatic anxiety, genital symptoms, hypochondriasis, loss of insight, and weight 
loss.46 Hamilton thought that four additional items of diurnal variation, depersonalization, 
paranoid symptoms, and obsessive symptoms could be included on ratings forms but 
should not be included in the final total score because these items either did not measure 
the intensity of depression or occurred too rarely to warrant inclusion.46 Although 21- and 
24-item versions of the HAM-D now exist, the 17-item version of the scale that was used 
in the Hypericum trial is the one most commonly used.44  HAM-D17 scores can range 
from 0-54. Depression severity increases as the score increases. A score of 0-7 usually 
indicates normal or remission of depression symptoms. A score of 20 or greater indicates 
moderate to severe depression. 
 The HAM-D is to be completed by clinicians using information obtained through 
a clinical interview. The items on the HAM-D are anchor-point descriptions of symptoms 
that are thought to be common in depression. Hamilton did not include a standardized 
interview for clinicians to use with the scale so the reliability of the scale is dependent on 
the clinician using it. Several structured interview guides have been developed in order to 
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improve the reliability of the scale.44 The Williams’ Structured Interview Guide for the 
Hamilton Depression Rating Scale has been found to improve the item reliability and 
facilitate rater training when compared to HAM-D ratings that are produced from 
unstructured interviews.48, 49  
  There has been much criticism of the HAM-D in the past fifty years, including 
that the scale is measuring a definition of depression that is only partially related to the 
common DSM-IV criteria for depression.50 The scale does not recognize symptoms of 
depression such as helplessness, hopelessness, and worthlessness that are now considered 
to be relevant to defining depression.51 Another criticism of the HAM-D is that its 
sensitivity to detect changes in depression severity is reduced when used with people who 
have higher levels of depression severity.51 It has also been suggested that the HAM-D 
total score has an inherent bias for tricyclic antidepressants since the scale includes three 
items about sleep and one item about weight gain.52 These items address common side 
effects of tricyclic antidepressants such as changes in appetite and weight and 
drowsiness. It appears that the HAM-D might also be affected by the side effects of 
SSRIs such as gastrointestinal symptoms, sleep disturbances, nervousness and agitation. 
These SSRI side effects might be confused with the depression symptoms in the HAM-D 
and thus people taking SSRIs might appear to have higher HAM-D scores and thus more 
severe depression.52 
 Depression severity can also be measured with the Clinical Global Impressions 
(CGI) scales. The CGI are two scales used in central nervous system trials to assess 
efficacy of treatment, usually as secondary outcome measures. The two scales are the 
CGI-Severity (CGI-S) and the CGI-Improvement (CGI-I). The CGI scales yield measures 
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of severity of illness (CGI-S), global improvement (CGI-I), and can include efficacy 
index of the interaction of therapeutic effectiveness and adverse reactions.53 These scales 
were originally designed to provide a way for a study clinician to globally assess a study 
participant’s condition before and then after receiving the study treatment.54 The CGI 
scales were first published by the National Institute of Mental Health as part of a manual 
of assessments to be used in studies of psychotropic drugs. With the CGI-S, a clinician 
evaluates a participant at baseline to answer the question “considering your total clinical 
experience with this particular population, how mentally ill is the patient at this time?” 
The clinician rates the severity of the participant’s illness on a 7-point scale where 1 is 
“normal, not at all mentally ill” and 7 equals “among the most extremely ill patients.” 
Following the study treatment, the clinician uses the CGI-S again or uses the CGI-I to 
measure the change from pre- and post-treatment. The CGI-I is often used in clinical 
trials of antidepressant drugs to characterize treatment response.3 For the 7-point CGI-I, 
the clinician determines if the participant’s disorder has improved, become worse, or 
stayed the same. On the CGI-I, 1 is “very much improved” and 7 is “very much worse.”  
The CGI scales have been adapted routinely used in clinical trials of psychotropic 
treatments for bipolar disorder, anxiety, and schizophrenia but not in depression.55 
Although the CGI is often used in depression trials, there is still debate over the scale’s 
specificity.56 The validity of the CGI might be less than ideal because it relies on the 
clinician to be able to compare the severity of one person’s illness to another’s based on 
subjective experience, there is no standard interviewer guide to use with the scale, and 





Given the heterogeneity of the diagnostic criteria for major depression, depression 
is likely a clinical syndrome or group of disorders rather than one distinct disease. People 
with depression can vary widely in terms of symptoms, comorbidities, clinical course, 
pathophysiology, severity, and treatment responsiveness.57, 58 In order to further refine the 
diagnostic criteria for major depression and predict response to antidepressant treatment, 
different subtypes of depression have been proposed throughout the history of psychiatry. 
The proposed subtypes are based on differences in symptoms, onset of depression, 
trajectory, and the severity of symptoms.57, 59-62 Subtypes have been found to be 
associated with different risk factors and characteristics.60 In order for a subtype to be 
clinically useful, the subtype should be able to predict treatment response and thus have 
implications for the selection of treatment.57  
Numerous distinct subtypes of major depression have been proposed, including 
psychotic depression, atypical depression, melancholic/endogenous depression, and 
anxious depression. While the distribution of such subtypes in the general population is 
unknown,63 it is believed that these subtypes are neither mutually exclusive nor 
exhaustive. Anxiety symptoms are very commonly comorbid with depression in general64 
and it has been observed that anxiety disorders tend to be comorbid with atypical 
depression.65 Additionally, in one study, 14% of participants met criteria for both 
melancholic depression and atypical depression.66 In a post-hoc analysis of the large 
Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, almost one 
quarter of participants met criteria based on the DSM-IV for melancholic depression. 
Seventy one percent of these participants with melancholic depression also had features 
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of anxious depression.67 In the same STAR*D post-hoc analysis, 47.7% of participants 
with nonmelancholic depression had anxious depression.  The different subtypes of 
depression also might not be stable and thus might vary by episode of depression. It is 
possible that a person might experience symptoms of melancholic depression during one 
episode but have anxious depression in another episode.67  
 Melancholic Depression 
 While the idea of melancholic depression is centuries-old,68 there is no widely 
accepted clinically useful definition. Melancholic depression is also sometimes referred 
to as “endogenous” depression, based on the idea that it is a type of depression that 
“grows from within” an individual.27 The Newcastle Scale, the Research Diagnostic 
Criteria,69 and several editions of the DSM  have all defined a version of melancholic 
depression. Although the concept of melancholic depression has been debated for many 
years, it was first formally included in the third edition of the DSM in 1980.67 
“Depression with melancholic features” is now one of two subtypes of major depression 
currently included in the DSM-IV.9 The DSM-IV criteria for melancholic features 
emphasize having either the loss of pleasure in activities or lack of reactivity to usually 
pleasurable stimuli. It also includes the presence of at least three of the following: distinct 
depressed mood, worse symptoms in the morning, waking up at least two hours earlier 
than usual, notable psychomotor agitation or retardation, significant weight loss, and 
excessive guilt. The DSM-IV criteria have been criticized as being imprecise, inadequate 
for use in making decisions about treatment, and for contributing to diagnostically 
heterogeneous samples in clinical trials.68 There is considerable controversy over how 
melancholic depression will appear in the upcoming DSM-5. This controversy centers on 
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whether melancholic depression should continue to be thought of as a category of 
depression features or if it should be recognized as a distinct syndrome.70 
Despite the lack of agreement over how to define melancholic depression, 
unreactive mood, guilt, changes in weight, lack of a precipitating event, and psychomotor 
disturbance have continually been the main diagnostic components.71, 72  A review of the 
available literature in 2005 determined that there is evidence that melancholic depression 
is distinct from nonmelancholic depression in terms of biological functioning, 
personality, treatment response and suicidality.73 The presence of psychomotor 
disturbance has been proposed as a marker of an underlying neuropathological process 
specific to melancholic depression.74 The distinct biology of melancholic depression 
appears to include having the long allele of the serotonin promoter polymorphism, loss of 
hippocampal volume, and intracellular signal transduction abnormalities.75-77 The 
melancholic subtype also seems to be at least partially determined by genetics since the 
subtype independently aggregates in families.59 Adding to the body of evidence pointing 
to melancholic depression having a distinct biological component, sleep patterns have 
been observed to differ for people with melancholic depression as compared to people 
with nonmelancholic depression.78 
Numerous demographic and clinical features are also associated with melancholic 
depression. Studies applying applied different versions of diagnostic criteria have found 
that people with melancholic depression, as compared to those with nonmelancholic 
depression, were more likely: to be older, to have more severe depression, to have better 
response to somatic treatment, and to have poorer response to psychotherapy.27 
Additionally, people with depression who are hospital inpatients are more likely to have 
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melancholic depression than those who are outpatients.79 In STAR*D, melancholic 
depression was associated with greater severity of depression as measured by the HAM-
D and the Quick Inventory of Depressive Symptomatology than was nonmelancholic 
depression.27 Having melancholic depression during the STAR*D trial was also related to 
a lower likelihood of symptom remission with standard antidepressants than was having 
nonmelancholic depression. Study investigators have hypothesized that this treatment 
resistance might be related to the presence of comorbid anxious depression.67  
 It is unclear if the presence of the melancholic subtype of depression is useful for 
the selection of medication for treating outpatients although it does appear to be useful 
with inpatients.67, 79 Evidence on how people with melancholic depression respond to 
different kinds of antidepressants is varied. It appears that the older classes of TCAs and 
MAOIs are more effective than placebo for treating melancholic depression.80-83 People 
with melancholic depression did not respond well to the SSRI citalopram in the first 
phase of STAR*D In the later study phases of STAR*D, however, the presence of 
melancholic depression did not predict a differential response to sertraline as compared to 
the sustained-release bupropion or sustained-release venlafaxine.84 Inpatient samples 
have demonstrated that SSRIs are not effective for people with melancholic depression.85  
It remains uncertain if this result indicates lower efficacy of all SSRIs for people with 
melancholic depression.  
 Anxious Depression 
 It has long been observed that depression and anxiety often co-occur.86 There is 
no accepted definition of anxious depression but it is often defined with a dimensional 
approach as major depression with high levels of anxiety symptoms.10, 87 It can also be 
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defined with a syndromal approach as major depression with a comorbid anxiety 
disorder.10 The dimensional approach seems more appropriate for clinical use because 
many people with major depression also have definite symptoms of anxiety but these 
symptoms might not be clearly discernible as distinct from the depression or might not 
fully qualify as an anxiety disorder under the DSM-IV or ICD-10 diagnostic criteria.88, 89 
Anxious depression is not included as a diagnosis separate from depression in either the 
DSM-IV or ICD-10 but there is evidence that it is a unique depression subtype.90 When 
defined using the dimensional approach, anxious depression seems to be a fairly common 
subtype of depression.91 Of people diagnosed with depression, 50-70% experience 
moderate levels of comorbid anxiety and 20-25% have severe levels of anxiety.92 
A score of 7 or greater on the Guy and Cleary anxiety/somatization factor of the 
HAM-D is often used in studies to determine the presence of anxious depression as 
defined as major depression with high levels of anxiety symptoms.10, 53, 93, 94 The 
anxiety/somatization factor includes items on psychic anxiety, somatic anxiety, 
gastrointestinal somatic symptoms, general somatic symptoms, hypochondriasis, and 
insight. According to the definition using the anxiety/somatization factor, 44-46% of 
participants in the STAR*D trial had anxious depression.10, 90 Anxious depression, when 
compared to nonanxious depression, is associated with greater severity of symptoms, 
greater functional impairment, greater chronicity of depression, and longer episodes of 
depression.10, 58, 90, 95, 96 It is also related to having more episodes of depression than 
nonanxious depression.58 People with anxious depression also appear to have an increase 
risk for committing suicide.22 People with anxious depression are more likely than those 
with nonanxious depression to report suicidal ideation and previous suicide attempts.58 
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In terms of treatment response, people with anxious depression tend to have 
poorer responses to antidepressant treatment than do people with nonanxious 
depression.91, 94 Results of previous studies are mixed but anxious depression does seem 
to be related to differential responses to different classes of standard antidepressants. In 
one study, greater severity of psychic and somatic anxiety symptoms of major depression 
at baseline predicted an increased likelihood of non-response to fluoxetine, regardless of 
depression severity at baseline.97 It appears that SSRIs might have a slight advantage over 
bupropion, a norepinephrine and dopamine reuptake inhibitor.91  In a pooled analysis of 
data from randomized controlled trials of the SSRI escitalopram, there was no difference 
in response to escitalopram, older SSRIs, or SNRIs.98 In contrast, the SNRI venlafaxine 
has appeared to be superior to the SSRI fluoxetine and to placebo in treating anxious 
depression.99 In another study, mirtazapine, a noradrenergic and specific serotonergic 
antidepressant, was more effective in reducing the symptoms of major depression with 
anxiety than paroxetine was during the first few weeks of treatment.100 This trial also 
indicated that reducing the anxiety symptoms quickly may increase treatment adherence.  
Interpreting results of treatment trials for anxious depression can be difficult since 
people with anxious depression also tend to experience a delayed treatment response.101 
Because of the delayed treatment response associated with comorbid anxiety and 
depression, people with anxious depression may need to be evaluated for a longer period 
of time than those with nonanxious depression. It has been suggested that people with 
anxious depression be evaluated for 9-12 weeks before the efficacy of a specific 
treatment is established.102 Standard antidepressants are generally thought to start 
producing measurable change in depression severity in 2-4 weeks following initiation of 
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treatment with some data suggesting onset of action might begin as soon as 3 days after 
treatment begins.103  
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Chapter 3: Research Design and Methods  
This thesis research is a secondary data analysis of longitudinal data from a 
clinical trial of St John’s wort for the treatment for major depression (ClinicalTrials.gov 
identifier NCT00005013). The publicly available limited access dataset used for this 
thesis was obtained from the National Institute of Mental Health (NIMH) through the 
institute’s standard data use certification process.104  
The Treatment of Major Depression with St John’s Wort Trial  
The Treatment of Major Depression with St John’s Wort trial, also known as the 
Hypericum trial, was a study sponsored by NIMH and the National Center for 
Complementary and Alternative Medicine to determine the acute antidepressant efficacy 
of a standardized extract of St John’s wort (LI-160) for the treatment of major 
depression.105 It was a double-blind, randomized, placebo-controlled trial in which 
participants received St John’s wort, the standard SSRI sertraline, or placebo. There was 
a one-week placebo run-in phase followed by randomization to St John’s wort, sertraline, 
or placebo.  This acute treatment phase lasted for 8 weeks. Assessments were completed 
weekly or biweekly until week 8. Participants who had a partial or full response by week 
8 of the acute phase could enter a 4-month continuation phase.  The main aim of the 
original Hypericum trial was to test if St John’s wort was superior to placebo after 
treatment for 8 weeks. Sertraline was included as an active comparator to calibrate the 
validity of the trial. The main result was that neither St John’s wort nor sertraline differed 
significantly from placebo on the change in HAM-D total score from baseline to week 8 





The Hypericum trial consisted of 340 adult outpatient participants who were 
recruited from 12 academic and community clinics between December 1998 and June 
2000.6 These participants had moderate to severe major depression as diagnosed with the 
modified Structured Clinical Interview for Axis I DSM-IV disorders.106 The inclusion 
criteria for the original Hypericum trial were: 1) at least 18 years of age, 2) moderate to 
severe depression as determined by a minimum total score of 20 on the 17-item HAM-D 
at screening and at baseline, 3) maximum score of 60 on the Global Assessment of 
Functioning at screening and at baseline, 4) HAM-D score cannot decrease by 25% or 
more between screening and baseline, 5) capacity to give informed consent and to follow 
study procedures, 6) identification of a close personal contact who would be notified of 
any clinical concerns, and 7) abstinence or effective contraception used throughout the 
duration of the study.  
 Details of enrollment and outcomes during the Hypericum trial are detailed in 
Figure 1. Four hundred twenty eight people entered the one-week placebo run-in period 
of the Hypericum trial. Three hundred forty people were randomized after the one-week 
run-in period.  One hundred eleven participants were assigned to sertraline, 113 
participants were assigned to St John’s wort, and 116 participants were assigned to 
placebo. In the main outcome paper of the original trial, it was reported that two 
participants in the sertraline group had HAM-D total scores below the enrollment 
requirement of a HAM-D of at least 20. In the original Hypericum trial outcomes 
analysis, these two people have been included in the baseline analysis but excluded from 
the efficacy analysis.  
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This thesis research used limited access data from the participants. The original 
protocol and consent forms were approved by the institutional review boards at each 
clinical site, Duke University Medical Center, and Research Triangle Institute 
International.107 Participants provided informed consent prior to entering the trial.  
During the consent process, participants were informed that they had 1 in 3 chances of 
receiving St John’s wort, sertraline, or placebo. The Hypericum trial was monitored by 
the NIMH Data and Safety Monitoring Board. All personal identifiers in the dataset used 
for this thesis were removed and other data elements modified by NIMH prior to 
releasing the dataset. This was done to reduce to likelihood that any individual participant 
can be identified from the data.  In order to access the data, the appropriate NIMH Data 
Use Certification and approval from the University of Maryland, College Park 
Institutional Review Board was obtained.  
Efficacy Measures 
Treatment Response 
The main outcome variable was response to treatment for depression. The primary 
measure was the incidence of response at week 8 or at early study termination. Response 
was defined as a HAM-D total score of 12 or less, a 50% reduction in HAM-D score, and 
a CGI-I score of 1 or 2.   
Severity of Depression 
  The CGI-S and CGI-I were ascertained as secondary outcome measures in the 
original Hypericum trial and were also reported separately from treatment response in 
this paper.  For the HAM-D and the CGI-S, a higher score indicates more severe 
23 
 
depression. A higher score on the CGI-I indicates a lack of improvement or worsening of 
symptoms. 
Functioning 
Functioning was defined as the general ability to carry out daily activities. 
Functioning was ascertained using scores on the Global Assessment of Functioning Scale 
(GAF) and the Sheehan Disability Scale (SDS).  The clinician-rated GAF is a numeric 
scale of 0-100 used by clinicians to assess social, occupational, and psychological 
functioning.  On the GAF, 0 indicates severe impairment and a persistent danger of 
severely hurting oneself or others while 100 indicates superior functioning in a variety of 
activities. The brief, self-report SDS assesses impairment in work, social life, and family 
life. The SDS ranges from 0-30. On the SDS, a score of 0 signifies unimpaired while a 
score of 30 is highly impaired. 
Independent Variables 
Subtype of Depression 
The original Hypericum trial did not classify participants according to depression 
subtype so classifying needed to be done post-hoc for the purposes of this study. Because 
a standard accepted way of identifying melancholic depression using scores on the HAM-
D17 does not presently exist, a modified version of the Hamilton Endogenomorphy 
Subscale (HES) for identifying melancholic depression was used in this analysis.108, 109 
The HES was modified for use in this thesis research because not all the HES items are 
asked in the 17-item version of the HAM-D that was used in the Hypericum trial. The 
version of the HES used here does not include items on diurnal variation and 
hopelessness. These two items are only available on the 24-item version of the HAM-D. 
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Additionally, the definition used here includes an item on guilt. Although guilt was not 
included in the original HES, it is included here because it is one of the factors in the 
DSM-IV criteria for major depression with melancholic features.9 The modified HES used 
in this study incorporated the items from the HAM-D17 that address depressed mood, 
guilt, late insomnia, retardation, agitation, and weight loss. Scores can range from 0-20. 
The presence of melancholic depression on the modified HES is indicated by a score of 9 
or greater. Nonmelancholic depression is considered to be having a modified HES score 
of 8 or less. 
Anxious depression was defined as major depression with high levels of anxiety 
symptoms as measured by a score of greater than or equal to 7 on the HAM-D 
anxiety/somatization factor derived by Cleary and Guy.110 This measure has been used in 
other studies to classify anxious depression.10 This factor includes the psychic anxiety, 
somatic anxiety, gastrointestinal somatic symptoms, general somatic symptoms, 
hypochondriasis, and insight factors on the HAM-D17. Scores for the HAM-D 
anxiety/somatization can range from 0 to 18.  
Treatment Assignment 
Participants were assigned at the beginning of the trial to receive St John’s wort, 
sertraline, or placebo. The St John’s wort extract was provided by Lichtwer Pharma and 
was standardized to be between 0.12% and 0.28% hypericin. Hypericin is one of the 
active components of St John’s wort. Sertraline was provided by Pfizer, Inc.  Following a 
week-long run-in period of placebo tablets, participants were given either 900 mg/d of St 
John’s wort, 50 mg/d of sertraline, or placebo. These treatments were given 3 times per 
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day. Daily doses of all treatments could be increased after week 3 or 4, depending on the 
severity of the participant’s depression during the study. 
Covariate 
The HAM-D total score at baseline, before treatment, was the main measure of the 
severity of depression symptoms at the beginning of the study.  This baseline score was 
used in the ANCOVA models as a covariate. 
Statistical Analysis 
The first task for analyzing the study data was to classify participants as having 
melancholic or nonmelancholic depression and having anxious or nonanxious depression. 
This was done according to the previously outlined melancholic and anxious HAM-D 
factor scores. In order to establish a cutoff point on the modified HES to define 
melancholic depression, the distribution of total scores on the modified HES was 
evaluated as was originally done by Thase et al.109 The distributions of total scores on the 
HAM-D anxiety/somatization factor were also examined to confirm whether a cutoff 
score of 7 should be used to determine anxious depression. Comparisons were not made 
between participants with anxious depression and those with melancholic depression 
because of the possibility that these two subgroups are not mutually exclusive.  
After participants were categorized having melancholic or nonmelancholic 
depression and as having anxious or nonanxious depression, baseline demographic and 
clinical features were compared for any significant differences among participants with 
melancholic versus nonmelancholic depression and with anxious versus nonanxious 
depression in order to determine if there were differences in the distributions of subtypes 
across the treatment groups at baseline. Demographic characteristics were age, sex, and 
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race. Clinical characteristics included length of current episode of depression, severity of 
depression at baseline, and level of functioning. Intent-to-treat analyses were performed. 
All 340 participants in the original Hypericum trial were included in these analyses, 
including analyses of baseline measures and analyses of results at week 8. This is in 
contrast to the original Hypericum trial’s primary outcomes analyses which included all 
340 participants in the baseline analyses but excluded 2 participants from the efficacy 
analyses because they did not meet the inclusion criteria of having a HAM-D total score 
of at least 20.6  
Descriptive statistics were calculated in order to characterize the baseline 
demographic and clinical characteristics of participants by subtype of depression. These 
statistics include frequencies and percentages for categorical variables and mean and 
standard deviations for continuous variables. T tests were used to determine if there were 
differences within each depression subtype for the continuous variables age and length of 
current episode of depression. Similarly, chi-square and Fisher exact tests were used for 
comparing differences for the categorical variables sex and race in each subtype of 
depression. Wilcoxon-Mann-Whitney U tests were used for the ordinal variables of 
depression severity at baseline and level of functioning. 
For each subtype of depression, an analysis of covariance (ANCOVA) model 
evaluated the severity of depression at the end of treatment as measured by HAM-D total 
score at week 8, with treatment and depression subtype level as main effects and baseline 
severity of depression as a covariate. Included in the model was the interaction term for 
treatment and subtype level in order to evaluate whether there is a differential response to 
treatment dependent on subtype level, e.g., in anxious depression versus nonanxious 
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depression. ANCOVA models were also used to obtain adjusted means of the other 
clinical characteristics.  
The percentage of study participants remaining in each treatment group at week 8 
was also compared within each subtype of depression using chi-square tests. Clinical 
characteristics and status of treatment response at week 8 by depression subtype were 
also examined for differences within subtypes of depression by treatment group. 
The last observation available was substituted for missing observations at week 8. 
With the last observation carried forward (LOCF) method, missing values are replaced 
with the most recently obtained value for the same participant. LOCF was used here in 
order to match the methods used in the primary outcome paper of the original Hypericum 
trial as closely as possible.6  LOCF is also used because it is unknown why missing 
observations occurred and thus it cannot be said with certainty that the missing 
observations were missing at random, completely at random, or were ignorable. Unlike in 
the original Hypericum trial, the LOCF imputation performed in this thesis was used for 
observations only as far back as week 2. This was done because it did not seem like a 
measurable response to treatment could have been detected unless the medication had 
been taken for at least two weeks. Because of this, some missing values of study 
measurements still remained in the dataset. 
Because of concern that the number of data substitutions would be high and thus 
the LOCF data might not accurately represent the true treatment outcome at week 8, 
mixed effects linear regression models were also fit for each depression subtype in order 
to utilize all available data points and thus possibly more accurately reflect the actual 
response. Linear, rather than quadratic, models were used because the means of the 
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outcomes variables appeared to decrease linearly with time. The models explored the 
effects of treatment, depression subtype level, and time on HAM-D total score. The time 
points included in these models were baseline and weeks 1-8. Comparisons on goodness 
of fit statistics AIC and BIC were made between compound symmetry, unstructured, 
compound heterogeneous symmetry, autoregressive, and heterogeneous autoregressive 
variance-covariance structures. 
The probability of achieving at least a moderate level of treatment response, 
versus no response, was also modeled for each depression subtype. Treatment response 
was examined using multivariate logistic regression. In each depression subtype, the 
logistic regression model examined the effect of predictor variables that included 
treatment assignment and depression subtype status at baseline. Of the treatment 
assignments, St John’s wort was compared to placebo and sertraline was compared to 
placebo. St John’s wort and sertraline were not directly compared to each other because 
the intent of the original Hypericum trial was to compare the efficacy of St John’s wort to 
placebo. Sertraline was originally used as an active comparator. 
The significance level for all analyses was set at a p-value of 0.05. All statistical 
analyses were performed using SAS 9.2 software (SAS Institute Inc., Cary, NC).  
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Chapter 4: Results 
In order to classify people as having melancholic or nonmelancholic depression, a 
cutoff point on the modified HES needed to be determined. Thase et al. validated the 
original HES in a group of 147 women outpatients with depression who were not 
receiving treatment and used HES ≥ 8 as the determination of having high levels of 
endogenous/melancholic depression.109 This differs from the work of Kovacs et al. that 
used HES ≥ 9 to indicate that people had high levels of endogenous/melancholic 
depression.108 Because a clinically validated and accepted cutoff score for the modified 
HES does not exist, the distribution of scores on the modified HES was examined. Figure 
2 displays the cumulative percentage of participants for each HES score. The frequency 
of participants for each HES score is displayed in Figure 3.  The cumulative percent for 
HES=9 was 56.76 and the frequency was n=193. Thus, for the purposes of this thesis, 
melancholic depression was defined as HES ≥ 9. Nonmelancholic depression was then 
defined as HES ≤8.  
Participants were categorized as having anxious depression or nonanxious 
depression according to scores on the HAM-D anxiety/somatization factor. As described 
in Chapter 3, a cutoff score of 7 or greater to indicate the presence of anxious depression 
was originally chosen based on recommendations in the literature. An examination of the 
distribution of anxiety/somatization factor scores in this Hypericum sample revealed that 
the cumulative percent for a score of 7 was 52.65 (Figure 4). The cumulative frequency at 
this score was 179 (Figure 5). This distribution confirmed that a score of 7 or greater 
should be used to delineate anxious depression from nonanxious depression. 
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The frequency of the melancholic and anxious depression subtypes in the 
Hypericum trial sample at baseline is displayed in Table 1. Slightly more than 64% of 
participants had at least melancholic depression. A little more than 71% of participants 
had at least anxious depression. Almost 43% of the sample had both melancholic and 
anxious depression. Approximately 29% of participants had both nonmelancholic and 
anxious depression. About 22% of participants had both melancholic and nonanxious 
depression. Less than 7% of participants had both nonmelancholic and nonanxious 
depression. 
 Baseline demographic and clinical characteristics of participants with 
melancholic and nonmelancholic depression are detailed in Table 2. Almost two-thirds of 
participants were classified as having melancholic depression (n=219) while 121 
participants had nonmelancholic depression. Significant differences between the 
melancholic and nonmelancholic groups were observed only for age and HAM-D, CGI-
S, GAF, and SDS total scores. People with melancholic depression were older on average 
than those with nonmelancholic depression. The mean age was 44.03 years for those with 
melancholic depression and 40.54 years for those with nonmelancholic depression  
(t(338) = -2.35, p = 0.02). The range of HAM-D total scores for people with melancholic 
depression was 18 to 33. The range of HAM-D total scores for people with 
nonmelancholic depression was 20-27. The average HAM-D total score was 23.51 for 
participants with melancholic depression and 21.17 for participants with nonmelancholic 
depression. People with melancholic depression had significantly higher ratings of 




(|z|1-α/2= 7.11, p < 0.0001). People with melancholic depression also had higher levels of 
depression severity according to the CGI-S than did people with nonmelancholic 
depression (|z|1-α/2= 4.39, p < 0.0001). In terms of levels of functioning, the melancholic 
depression group had significantly higher levels of functional impairment according to 
scores on the SDS but had lower impairment according to scores on the GAF than did the 
nonmelancholic depression group (|z|1-α/2= 2.40, p = 0.02 and |z|1-α/2= 2.40, p = 0.02, 
respectively).  
Baseline characteristics of participants with anxious or nonanxious depression are 
detailed in Table 3. Almost 72 percent of participants were classified as having anxious 
depression (n=244) versus nonanxious depression (n=96) at baseline. For the anxious 
subtype, there were no significant differences among the demographic characteristics. Of 
the clinical characteristics, differences between the anxious and nonanxious groups were 
significant for HAM-D, CGI-S, and SDS total scores but not for GAF score. People with 
anxious depression had significantly higher levels of depression severity than did those 
with nonanxious depression according to HAM-D score (|z|1-α/2= 7.39, p <0.0001) and 
CGI-S (|z|1-α/2 = 2.08, p = 0.04).  People with anxious depression also had significantly 
more functional impairment as measured by SDS total score than did people with 
nonanxious depression (|z|1-α/2= 2.06, p = 0.04). 
Differences in baseline clinical and demographic characteristics of the 
melancholic subtype were also compared by treatment assignment within each level of 
the depression subtype (Table 4). Differences by treatment group for sex, race, and length 
of current depression episode were not significant. For age, the only significant difference 
32 
 
was for those assigned to receive sertraline. In the sertraline group, people with 
melancholic depression were older than those with nonmelancholic depression  
(t(109) = -2.04, p = 0.04). People with melancholic depression who were assigned to 
sertraline had the highest mean age of all treatment groups. In all treatment assignments, 
people with melancholic depression had higher levels of depression severity according to 
HAM-D and CGI-S scores than did the people with nonmelancholic depression. The 
differences in HAM-D scores were significant for the people assigned to St John’s wort  
(|z|1-α/2 = 5.64, p < 0.0001), to placebo (|z|1-α/2 = 3.61, p = 0.0003), and to sertraline  
(|z|1-α/2 = 2.94, p = 0.003). The differences in CGI-S scores between melancholic and 
nonmelancholic depression groups were significant for the people receiving St John’s 
wort (|z|1-α/2 = 2.65, p = 0.008), for those receiving placebo (|z|1-α/2 = 2.65, p = 0.008), and 
those receiving sertraline (|z|1-α/2 = 2.25, p = 0.02). People with melancholic depression 
assigned to receive St John’s wort had the highest mean severity of depression. Of those 
assigned to receive St John’s wort, people with melancholic depression had higher levels 
of functioning as measured by GAF scores compared to people with nonmelancholic 
depression (|z|1-α/2= 2.36, p = 0.02). Differences in GAF scores were not significant for 
people assigned to receive placebo or sertraline. When functioning was measured by SDS 
total score, people with melancholic depression assigned to the placebo group were 
significantly more impaired than those in the placebo group with nonmelancholic 
depression (|z|1-α/2 = 2.33, p = 0.02). Differences in SDS total scores were not significant 
for people receiving St John’s wort or sertraline. 
The baseline clinical and demographic characteristics of participants by treatment 
group for the two levels of the anxious depression subtype are available in Table 5. There 
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were no significant differences for the variables of sex, race, and length of current 
depression episode by treatment group. In the St John’s wort group, people with anxious 
depression were significantly older than those with nonanxious depression  
(t(111) = -2.06, p = 0.04). Conversely, in the sertraline group, people with anxious 
depression were significantly younger than those with nonanxious depression  
(t(109) = 2.92, p = 0.004). There was not a significant difference in age for the placebo 
group. People with anxious depression had higher levels of depression severity than did 
people with nonanxious depression in all the treatment groups, according to HAM-D 
score: St John’s wort: (|z|1-α/2= 3.43, p = 0.0006), placebo: (|z|1-α/2 = 4.54, p <0.0001), and 
sertraline: (|z|1-α/2 = 4.69, p < 0.0001). In the placebo group, people with anxious 
depression had significantly higher severity according to CGI-S score than did people 
with nonanxious depression (|z|1-α/2 = 2.17, p = 0.03). Differences in CGI-S were not 
significant for the St John’s wort or sertraline groups.  Differences in GAF and SDS total 
scores were also not significant by treatment group. 
When study continuation was defined as having a HAM-D score at week 8 of 
treatment, 245 participants, or 72%, remained in the study at week 8. Ninety five people 
discontinued before week 8. As seen in Table 6, study continuation rates at week 8 were 
similar for people with melancholic depression and nonmelancholic depression. There 
were no significant differences in study continuation rates between melancholic and 
nonmelancholic depression groups by treatment assignment. As seen in Table 7, study 
continuation rates were also similar for people with anxious depression and nonanxious 
depression. There was no significant difference in the continuation rates for people with 
anxious versus nonanxious depression by treatment assignment.   
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Rates of treatment response (response versus no response) at week 8 by treatment 
group for those with melancholic and nonmelancholic depression are shown in Table 8. 
In each treatment by melancholic depression subtype group, more than half of 
participants did not respond to treatment. Response rates, however, did not differ 
significantly between the melancholic and nonmelancholic depression groups. There 
were also no significant differences in treatment response rates by treatment group. For 
the anxious depression subtype, rates of treatment response at week 8 are shown in Table 
9. In each treatment by anxious depression subtype group, more than half of participants 
did not respond to treatment. Rates of treatment response did not differ significantly 
between the anxious and nonanxious depression groups. There was also no significant 
difference within each treatment group by subtype. 
As shown in Table 10, the primary ANCOVA using LOCF revealed no 
significant main effects for treatment (F2,300 = 1.77, p = 0.17) or melancholic depression 
status at baseline (F1,300 = 1.1.7, p = 0.28) on depression severity at week 8. The covariate 
of depression severity at baseline was significant (F1,300 = 24.58, p < 0.0001). There was 
no significant interaction between treatment and baseline melancholic depression subtype 
level (F2,300 = 0.93, p = 0.40). Melancholic depression status at baseline did have a 
significant effect on CGI-S score at week 8 (F1,301 = 4.59, p = 0.03) after controlling for 
baseline severity of depression. The ANCOVA models demonstrated that of the people 
assigned to St John’s wort, the melancholic depression group had higher mean HAM-D, 
CGI-S, and CGI-I total scores at week 8 (Table 11). These means were adjusted for 
HAM-D score at baseline. In the placebo group, the mean adjusted HAM-D, CGI-S, 
CGI-I scores were higher for the melancholic depression group than for the 
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nonmelancholic depression group. Conversely, in the sertraline group, the mean adjusted 
HAM-D, CGI-S, CGI-I scores were higher for the people in the nonmelancholic group 
than in the melancholic group. The nonmelancholic depression group assigned to placebo 
had the highest adjusted mean HAM-D score at week 8. The primary ANCOVA revealed 
no significant main effects for treatment (F2,300 = 1.77, p = 0.17) or melancholic 
depression status at baseline (F1,300 = 1.1.7, p = 0.28) on depression severity at week 8. 
The covariate of depression severity at baseline was significant (F1,300 = 24.58, p < 
0.0001). There was no significant interaction between treatment and baseline melancholic 
depression subtype level (F2,300 = 0.93, p = 0.40). Melancholic depression status at 
baseline did have a significant effect on CGI-S score at week 8 (F1,301 = 4.59, p = 0.03) 
after controlling for baseline severity of depression.  
As seen in Table 12, the primary ANCOVA model revealed no main effects for 
treatment (F2,300 =2.74, p = 0.07) or anxious depression status (F1,300 = 0.04, p = 0.84) on 
depression severity at week 8. There was no significant interaction between treatment and 
subtype level (F2,300 =0.72, p = 0.49). The covariate of depression severity at baseline 
was significant (F1,300=22.40, p < 0.0001). Treatment had a significant effect on CGI-S 
score (F1,301 = 3.23, p = 0.04) and on CGI-I (F1,301 = 3.23, p = 0.03) after controlling for 
baseline severity of depression. The ANCOVA models for the anxious depression 
subtype showed that, of those who were assigned St John’s wort, the anxious depression 
group had lower mean HAM-D, CGI-S, and CGI-I scores when adjusted for baseline 
depression severity than did the nonanxious depression group (Table 13). Of the people 
assigned to placebo and sertraline, the nonanxious depression groups had lower mean 
HAM-D, CGI-S, and CGI-I scores than did the anxious depression groups, when means 
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were adjusted for baseline severity of depression. The nonanxious depression St John’s 
wort group had the highest adjusted HAM-D total score of all the treatment by anxious 
depression subtype groups.  
For the mixed effects regression model of longitudinal HAM-D scores in the 
melancholic depression subtype, an unstructured covariance structure was used after 
comparing the goodness of fit statistics AIC and BIC. Because of the randomization that 
was originally done following the run-in phase of the trial, the model was not adjusted for 
additional covariates. Observations included in this model were those available at 
baseline and weekly from weeks 1-8. The type 3 fixed effects for the model and the 
solution for fixed effects indicated that HAM-D scores decreasing over time  
(F2,1617 = 569.87, p < 0.0001), with an estimated decrease of 1.18 points per unit of time 
(p  <0.0001). The type 3 tests of fixed effects also showed that there were significant 
effects of melancholic depression status at baseline (F1,1617 = 26.10, p < 0.0001).  
However, the interaction of treatment assignment by melancholic depression status at 
baseline is also significant (F2,1617 = 5.81, p = 0.003) and therefore supersedes the main 
effect of melancholic depression status. In the interaction of treatment by melancholic 
depression status at baseline, people with nonmelancholic depression assigned to St 
John’s wort have a lower estimated HAM-D total score when compared to those with 
melancholic depression assigned to St John’s wort (p = 0.0009). 
 An unstructured covariance structure was also used for the mixed effects 
regression model of longitudinal HAM-D scores in the anxious depression subtype due to 
this structure having the smallest AIC and BIC of the structures evaluated. The model 
was not adjusted for covariates because of the randomization that was done in the trial 
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after the run-in phase. Observations included in this model were those available at 
baseline and weekly from weeks 1-8. As shown in Table 15, the type 3 tests of fixed 
effects for the model showed significant effects for treatment (F2,1951 = 6.94, p = 0.001), 
anxious depression status at baseline (F1,1951 = 84.83, p < 0.0001), and time  
(F1,319 = 304.17, p < 0.0001). The solution for fixed effects showed that HAM-D total 
scores were predicted to be lower for people with nonanxious depression than for people 
with anxious depression (p < 0.0001), holding all other variables constant. HAM-D 
scores also decreased with time (p < 0.0001), holding all other variables constant.  
 Multivariate logistic regression models were used to examine the effects of 
depression subtype and treatment assignment in the probability of achieving treatment 
response. However, as shown in Table 16, none of these odds ratios were statistically 
significant.  Results were similar for the logistic regression for the anxious depression 
subtype. As shown in Table 17, none of the odds ratios was statistically significant.   
 The clinical characteristics of participants at week 8 were examined by subtype 
and treatment response. In the melancholic depression group, those who did not respond 
to treatment had more severe depression and were more functionally impaired when 
compared to people with who did respond to treatment across all measures (p <0.0001 for 
HAM-D, CGI-S, GAF, and SDS scores) (Table 18). As can thus be expected, those who 
did not respond to treatment showed less improvement in depression severity as 
measured by the CGI-I (p <0.0001). Results were similar in the nonmelancholic 
depression group in that the differences in clinical measures were significantly different 
between those who responded to treatment and those who did not (p <0.0001 for HAM-
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D, CGI-S, GAF, and SDS scores).  These differences also held true for the anxious versus 
nonanxious depression groups (Table 19).  
 When the clinical scores at week 8 for participants in with melancholic or 
nonmelancholic depression were examined by treatment assignment, there were 
significant differences in all scores between the group with melancholic depression who 
responded and those who did not (Table 20). The group with melancholic depression 
assigned to St John’s wort who did not respond had the highest mean HAM-D and CGI-S 
scores of all the treatment groups. Differences between those who responded and did not 
in the melancholic group were significant for HAM-D, CGI-S, CGI-I, and GAF scores 
for all treatment assignments (p <0.001). In the nonmelancholic group, the difference in 
SDS score was significant for people assigned to St John’s wort (p = 0.03) and for people 
assigned to placebo (p = 0.001). Differences were also significant between those who did 
and did not respond by treatment assignment in anxious depression group (p <0.05) 




Chapter 5: Discussion  
The Hypericum trial appears to have enrolled high numbers of people with 
melancholic depression and with anxious depression, with higher rates of melancholic 
depression and anxious depression than have been seen in trials like STAR*D. Study 
results did not support the hypothesis that people with melancholic depression would be 
more likely than people with nonmelancholic depression to be male and have a shorter 
duration of current depressive episode. Participants with melancholic depression were, 
however, found to be significantly older, to have more severe depression, and to have 
more functional impairment than participants with nonmelancholic depression. The 
hypothesis that participants with anxious depression were more likely than participants 
with nonanxious depression to have more severe depression and more functional 
impairment was confirmed. Participants with anxious depression, however, were not 
found to be more likely than participants with nonanxious depression to be female. 
 Contrary to the original hypothesis, neither depression subtype nor treatment 
assignment appeared to have an effect on study continuation by week 8. Response rates 
also did not appear to be influenced by depression subtype or treatment assignment. 
People with melancholic depression were not significantly more likely than those with 
nonmelancholic depression to respond to treatment with St John’s wort or with sertraline. 
Also, people with melancholic depression were not less likely than those with 
nonmelancholic depression to respond to placebo. People with anxious depression were 
not significantly less likely than people with nonanxious depression to respond to 
treatment with St John’s wort or sertraline. People with anxious depression were not 
significantly more likely than those with nonanxious depression to respond to placebo.  
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 There were several differences between the ANCOVA models with LOCF and 
the mixed effects linear regression models for HAM-D total scores in both the 
melancholic and anxious subtypes. The ANCOVA for the melancholic subtype did not 
find a main effect of treatment assignment, melancholic depression status at baseline, or 
the interaction between treatment and subtype status for depression severity at the end of 
treatment. A significant effect for treatment was also not found in the mixed effects 
model. The mixed effects model, however, demonstrated a significant influence of 
melancholic depression status at baseline and for the interaction between treatment 
assignment and baseline melancholic status. In the anxious depression subtype, the 
ANCOVA also did not find that anxious depression status at baseline, treatment 
assignment, and the interaction between anxious depression status and treatment 
assignment were significant main effects. The mixed effects regression model showed 
significant effects for treatment and anxious depression status at baseline but not for the 
interaction of the two. Given the methodological flaws associated with assuming one 
week’s outcome will hold true for the next week, as is the practice in LOCF, the mixed 
effects regression model might be a better indicator of true effects. 
 Depression subtype does appear to be at least somewhat related to depression 
severity throughout treatment but it is difficult to use subtype status as a predictor of 
treatment response. The discrepant findings between the ANCOVA, mixed effects 
regression, and logistic regression analyses seem to indicate that additional research 
needs to be conducted. St John’s wort appeared to be more effective for people with 
nonmelancholic depression rather than melancholic depression. Sertraline seemed more 
effective for people with nonanxious versus anxious depression and for people with 
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melancholic versus nonmelancholic depression. Placebo seemed more effective for 
people with nonanxious versus anxious depression and for people with nonmelancholic 
versus melancholic depression. These effects should be interpreted with more than a 
modicum of caution though, since effects were not consistently significant. 
Study Strengths and Limitations 
This study has several strengths. Since this was a secondary data analysis from a 
trial conducted by experienced academic researchers with funding and oversight by the 
federal government, the conduct of the original trial is presumed to be free of conflict of 
interest that might have biased the results. The results of this study can be used to 
generate hypotheses for future studies that could have practical clinical implications for 
developing personalized medicine for depression. An additional strength is that the 
operational definitions of several variables such as depression severity at baseline, the 
criteria for anxious depression, and treatment response have been used in other studies. 
This should allow for comparisons to be made across similar studies.  
 While this study has several strengths, there are also numerous limitations. Since 
this is a secondary data analysis, the variables are limited to what was originally 
collected. The influence of typical demographic variables such as education, income, and 
marital status could not be analyzed because they were not included in the original trial 
assessments. Additionally, the atypical depression subtype could not be included because 
the original trial did not ask about some of the distinguishing atypical features such as 
hypersomnia and rejection sensitivity. Another limitation inherent in using the 
Hypericum trial data instead of designing a new study is that people might not have been 
followed long enough to adequately capture the treatment effect. Anxious depression, in 
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particular, has been associated with delayed treatment response and it is possible that the 
original 8-week trial was not long enough to capture response. Furthermore, analysis of 
outcome was limited to interpretations of HAM-D, CGI-S, and CGI-I. These measures 
might not be the best indicators of treatment response. Additionally, the quality, 
including the inter-rater reliability, of the ratings of these measures is unknown. The 
quality of the clinical interviews during which these ratings has been previously shown to 
impact the ability separate the effects of active drug from placebo.111 
 Because the original randomization did not consider depression subtype, people 
with anxious depression and those with melancholic depression were not equally 
distributed throughout the treatment groups. Additionally, using scores on the modified 
HES to identify melancholic depression might not be a clinically valid method. The 
criteria for melancholic depression might have been overly broad or strict, thus possibly 
misclassifying people on the melancholic subtype. The HAM-D anxiety/somatization 
factor accounts for a limited amount of anxiety symptoms and thus might not have 
adequately identified all the participants who had anxious depression.  
In general, because the Hypericum trial had numerous inclusion and exclusion 
criteria, it is possible that the sample of participants was overly homogenous and thus 
these results do not adequately represent effects that might be found in real-world clinical 
settings. An analysis of participants in the STAR*D trial, a trial which had broad 
inclusion criteria, demonstrated that regular phase III depression intervention trials do not 
recruit typical depression patients.112 This analysis estimated that less than one in four 
people with depression would be eligible for a typical trial. The Hypericum trial 
exclusion criteria might have particularly reduced variability in the predictor variables. 
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Excluding those with a positive drug urine screen or those at risk for suicide might have 
disproportionately excluded people with anxious depression since people with anxious 
depression have an increased risk of suicide and drug abuse.10, 22, 90, 97 Furthermore, the 
generalizability of the Hypericum trial results could be further compromised by the 
characteristics of people interested in receiving CAM treatment. Given that people who 
use CAM therapies for mental disorders tend to differ on sociodemographic and clinical 
variables compared to people who do not use CAM, participants in trials of CAM 
therapies might not adequately represent the general population.37   
Efficacy also might not have been demonstrated in the Hypericum trial because of 
issues with treatment adherence. Because St John’s wort is readily available as an over-
the-counter supplement, participants randomized to placebo or sertraline might have been 
able to independently take St John’s wort in addition to their assigned treatment. Another 
post-hoc analysis of the Hypericum trial did indeed find that, based on blood tests, 17% 
of participants assigned to placebo had taken St John’s wort.107 Treatment adherence 
could also have been compromised if people did not take all doses of their treatment 
assignment throughout the trial. This might have been more likely in the active treatments 
of St John’s wort and sertraline due to possible side effects. Adverse events were more 
frequent in the St John’s wort and sertraline groups in the original trial although it is 
unclear if these events impacted treatment adherence.6  
Using the LOCF imputation technique for missing observations at week 8 likely 
produced inaccurate estimates of response. LOCF could have led to bias in 
underestimating or overestimating the effect of treatment. Previous studies have shown 
that LOCF can favor the experimental treatment or placebo.113 To avoid the effects of 
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missing data on analysis, future studies should be designed to reduce as much participant 
attrition as possible by minimizing participant burden and treatment side effects.114 Since 
it is likely that there will always be some missing observations in trials, studies should 
also explore analyzing data using mixed-effects regression models, multiple imputation, 
or nonignorable models, as appropriate.115   
Conclusion 
This study explored the effect of the melancholic and anxious depression subtypes 
on response to treatment with St John’s wort, placebo, or sertraline. This work 
contributes to the body of literature on personalized medicine for major depression by 
exploring how to predict what treatments will work well for a particular person with 
depression. Current treatments fail to produce complete symptom remission in many 
people with depression. If it were possible to accurately predict who would respond to 
what treatment, treatment efficiency could be increased and the public health burden of 
depression could be decreased. Being able to differentiate treatment responses between 
people with depression could contribute to the determination of a biological mechanism 
of depression. This study also adds to the understanding of how well CAM treatments 
work for major depression. Clinicians need a better understanding of the evidence about 
the usefulness of CAM treatments for depression.116  
While this thesis research provides a unique contribution to the field, additional 
research is necessary to provide conclusive evidence of how depression subtypes do or do 
not moderate treatment response. In addition to determining the etiology of major 
depression, a large longitudinal epidemiologic study examining the prevalence of the 
depression subtypes in the general population would be very valuable in informing 
45 
 
clinician decision-making.63 Clinical trials of treatments that randomize participants 
according to subtype might also provide more conclusive evidence regarding whether or 
not depression subtypes moderate antidepressant treatment response.  New studies might 
also want to consider the instability of depression subtypes over time and examine how 





Table 1: Frequency of melancholic and anxious depression subtypes in the Hypericum 
trial  
  
No. (% of total population) Melancholic Nonmelancholic Total 
Anxious  146 (42.94) 98 (28.82) 244 (71.76) 
Nonanxious 73 (21.47) 23 (6.76) 96 (28.24) 




Table 2: Baseline demographic and clinical characteristics of participants with 









Age, mean (SD), yrs 44.03 (13.23) 40.54 (12.90) 0.02 
Sex, No. (%) 0.87 
Male 74 (33.79) 42 (34.71)  
Female 145 (66.21) 79 (65.29)  
Race, No. (%) 0.25 
Asian/ 
Pacific Islander 
6 (2.74) 8 (6.61)  
Black 25 (11.42) 10 (8.26)  
White 163 (74.43) 94 (77.69)  
Hispanic 21 (9.59) 6 (4.96)  
Native American 1 (0.46) 1 (0.83)  
Other 3 (1.37) 2 (1.65)  
Duration of current depression  
episode, No. (%) 
0.42 
<6 mos 60 (27.40) 32 (26.45)  
6-24 mos 99 (45.21) 38 (31.40)  
>24 mos 60 (27.40) 51 (42.15)  
HAM-D total score, mean 
(SD) 
23.51 (2.80) 21.17 (1.74) < 0.0001 
CGI-S score, mean (SD) 4.31 (0.52) 4.09 (0.37)  < 0.0001 
GAF total score, mean 
(SD) 
53.23 (4.75) 54.36 (4.37) 0.02 
SDS total score, mean 
(SD) 
16.27 (8.18) 14.11 (7.71) 0.02 
Abbreviations: HAM-D = Hamilton Depression Rating Scale, CGI-S = Clinical Global 
Impression Severity, GAF = Global Assessment of Functioning, SDS = Sheehan Disability Scale 
* Lower clinical scores denote less severity or impairment, except for the GAF. For the GAF, 
lower scores denote more functional impairment. 
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Table 3: Baseline demographic and clinical characteristics of participants with anxious 








Age, mean (SD), yrs 42.38 (12.68) 43.82 (14.45) 0.37 
Sex, No. (%) 0.48 
Male 86 (35.25) 30 (31.25)  
Female 158 (64.75) 66 (68.75)  
Race, No. (%) 0.43 
Asian/ 
Pacific Islander 
12 (4.92) 2 (2.08)  
Black 27 (11.07) 8 (8.33)  
White 181 (74.18) 76 (79.17)  
Hispanic 20 (8.20) 7 (7.29)  
Native American 2 (0.82) 0  
Other 2 (0.82) 3 (3.13)  
Duration of current depression  
episode, No. (%) 
0.07 
<6 mos 75 (30.74) 18 (18.56)  
6-24 mos 91 (37.30) 46 (47.42)  
>24 mos 78 (31.97) 33 (34.02)  
HAM-D total score, mean 
(SD) 
23.41 (2.75) 21.19 (1.51) <0.0001 
CGI-S score, mean (SD) 4.26 (0.49) 4.17 (0.45) 0.04 
GAF total score, mean (SD) 53.56 (4.62) 53.81 (4.70) 0.66 
SDS total score, mean (SD) 16.00 (8.10) 14.19 (7.88) 0.04 
Abbreviations: HAM-D = Hamilton Depression Rating Scale, CGI-S = Clinical Global 
Impression Severity, GAF = Global Assessment of Functioning, SDS = Sheehan Disability 
Scale 
* Lower clinical scores denote less severity or impairment, except for the GAF. For the GAF, 











Table 4: Baseline demographic and clinical characteristics of participants with melancholic versus nonmelancholic depression, 

































Sex, No. (%)  0.08  0.052  0.57 
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Table 4, continued: Baseline demographic and clinical characteristics of participants with melancholic versus nonmelancholic 




















Duration of current  
depression episode,  
No.(%) 
0.07  0.37  0.40 



























































































































































































































Native American 0 0  1  
(1.18) 
0  1  
(1.32) 
0  
Other 1  
(1.20) 
1 (3.33)  0 1  
(3.23) 









Table 5, continued: Baseline demographic and clinical characteristics of participants with anxious versus nonanxious 





















Duration of current 
depression episode,  
No. (%) 
0.14   0.90   0.09 






































































































Abbreviation: SJW = St John’s wort, Anx = anxious depression, Nonanx = nonanxious depression 
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Table 6: Comparison of study retention rates at week 8 of treatment for participants with 
melancholic versus nonmelancholic depression, by treatment group  
 
Note: Study retention is defined as having a HAM-D score at week 8 of treatment 
 
*Percentages in cells are of number of participants in treatment assignment by depression subtype 
status. For example, 57 of the 74 participants (77.0%) with melancholic depression in the St 
John’s wort group remained in the study at week 8.   
 
 
 Study participants remaining at  
week 8 
 
No (%) SJW Placebo Sertraline Total 
Melancholic depression at 
baseline 
57 (77.0) 55 (76.4) 50 (68.5) 162 (74) 
Nonmelancholic depression at 
baseline 
25 (64.1) 29 (65.9) 29 (76.3) 83 (69) 
p 0.14 0.22 0.43 0.27 
Total  82 (72.6) 84 (72.4) 79 (71.2) 245 (72.1) 
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Table 7: Comparison of study retention rates at week 8 of treatment for participants with 
anxious versus nonanxious depression, by treatment group 
 
Note: Study retention is defined as having a HAM-D score at week 8 of treatment 
 
 Study participants remaining at  
week 8 
 
No. (%) SJW Placebo Sertraline Total 
Anxious depression at baseline 64 (77.1) 59 (69.4) 54 (71.1) 177 (72.5) 
Nonanxious depression at 
baseline 
18 (60.0) 25 (80.6) 25(71.4) 68 (69.4) 
p 0.07 0.23 0.94 0.66 
Total 82 (72.6) 84 (72.4) 79 (71.2) 245 (72.1) 
*Percentages in cells are of number of participants in treatment assignment by depression subtype 
status. For example, 64 of the 83 participants (77.1%) with anxious depression in the St John’s 
wort group remained in the study at week 8.   
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Table 8: Clinical response rates of participants with melancholic versus nonmelancholic 
depression at week 8, by treatment group 
 
*Any response = HAM-D less than or equal to 12, 50% reduction in HAM-D score from baseline 
to end of treatment, and a CGI-I score of 1 or 2. LOCF is being used for HAM-D and CGI-I 
scores. 
Abbreviations: SJW=St John’s wort, Mel = melancholic depression, Nonmel = nonmelancholic 
depression 
 SJW Placebo Sertraline  
Response*,  
No. (%) 


















































Table 9: Clinical response rates of participants with anxious versus nonanxious 
depression at week 8, by treatment group 
 
 SJW Placebo Sertraline  
Response*,  
No. (%) 
Anx Nonanx Anx Nonanx Anx 
 
Nonanx Total 











































*Any response = HAM-D less than or equal to 12, 50% reduction in HAM-D score from baseline 
to end of treatment, and a CGI-I score of 1 or 2. LOCF used for HAM-D and CGI-I scores. 










































Outcome* F (p) F (p)** F (p F (p) 
HAM-D total 
score 




F1,300 = 1.17 
(0.28) 
F2,300 = 0.93 
(0.40) 




F1,301 = 4.59 
(0.03) 
F2,301 = 0.31 
(0.73) 




F1,301 = 3.02 
(0.08) 
F2,301 = 1.19 
(0.31) 




F1,301 = 3.05 
(0.08) 
F2,301 = 0.46 
(0.63) 






F2,234 = 0.61 
(0.55) 
* LOCF scores are used for the clinical characteristics, except for SDS total score. SDS total 
score is not using LOCF because SDS was only assessed as baseline and week 8 
** F statistics correspond to the type III SS 
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Table 11: Adjusted means of clinical characteristics at week 8 of participants with 
melancholic versus nonmelancholic depression, by treatment group  
 
Note: means are adjusted for severity of depression at baseline, as measured by HAM-D 
total score* 
 













HAM-D total score, mean  13.83 12.78 11.21 13.22 14.81 12.73 
CGI-S score, mean  3.10 2.95 2.72 3.28 3.39 3.04 
CGI-I score, mean 2.54 2.36 2.11 2.51 2.86 2.45 
GAF total score, mean 65.46 66.82 67.31 64.72 63.06 63.52 
SDS total score, mean 11.48 10.38 11.68 11.75 11.90 10.24 
* Dependent variable used week 8 HAM-D total if available (n=245) or last available observation 
after week 1 (n=62). 33 cases not included in analysis due to lack of observations beyond week 1. 
** LOCF scores are used for the clinical characteristics, except for SDS total score. SDS total 




























F1,300= 0.04 (0.84) F2,300= 0.72(0.49) 




F1,301= 0.00 (0.99) F2,301 = 1.71(0.18) 


















F1,234= 1.01 (0.31) F2,234= 0.17(0.84) 
* LOCF scores are used, except for SDS total score. SDS total score is not using LOCF because 
SDS was only assessed as baseline and week 8 
** F statistics correspond to the type III SS
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Table 13: Adjusted means of clinical characteristics at week 8 of participants with 
anxious versus nonanxious depression, by treatment group 
 
Note: means are adjusted for severity of depression at baseline, as measured by HAM-D 
total score* 
* Dependent variable used week 8 HAM-D total if available (n=245) or last available observation 
after week 1 (n=62). 33 cases not included in analysis due to lack of observations beyond week 1. 
** LOCF scores are used for the clinical characteristics, except for SDS total score. SDS total 
score is not using LOCF because SDS was only assessed as baseline and week 8 
 
 













HAM-D total score, mean 13.2 13.6 12.0 14.9 13.4 11.1 
CGI-S score, mean 3.07 3.18 2.87 3.44 2.94 2.73 
CGI-I score, mean 2.52 2.67 2.24 2.86 2.59 2.21 
GAF total score, mean 65.4 65.1 65.3 64.5 66.4 67.8 
SDS total score, mean 11.4 10.2 10.9 12.1 12.4 11.8 
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Table 14: Solutions for fixed effects and type 3 tests of fixed effects in the mixed effects 
















Solutions for Fixed Effects 
Effect Estimate Standard 
Error 
p 
Intercept 21.25 0.44 <0.0001 
Treatment assignment (sertraline 
vs placebo) 
0.06 0.63 0.92 
Treatment assignment (SJW vs 
placebo) 
1.93 0.62 0.002 
Melancholic depression  
(nonmelancholic vs melancholic) 
-0.69 0.72 0.34 
Time -1.18 0.05 <0.0001 
Sertraline by melancholic status 
(nonmelancholic vs melancholic) 
-1.02 1.04 0.33 
SJW by melancholic status 
(nonmelancholic vs melancholic) 
-3.46 1.04 0.0009 
Type 3 Tests of Fixed Effects 
Effect Fdf num, df den p 
Treatment assignment  F2,1617=0.79 0.45 
Melancholic depression status at baseline F1,1617=26.10 <0.0001 
Time F1,319=569.87 <0.0001 
Treatment assignment at baseline by 




Table 15: Solutions for fixed effects and type 3 tests of fixed effects in the mixed effects 




Solutions for Fixed Effects 
Effect Estimate Standard 
Error 
p 
Intercept 21.83 0.26 <0.0001 
Treatment assignment 
(sertraline vs placebo) 
-0.39 0.38 0.30 
Treatment assignment 
(SJW vs placebo) 
0.47 0.36 0.19 
Anxious depression  
(nonanxious vs 
anxious) 
-3.12 0.49 <0.0001 
Time -1.19 0.07 <0.0001 
Sertraline by anxious 
status (nonanxious vs 
anxious) 
0.36 0.69 0.60 
SJW by anxious status 
(nonanxious vs 
anxious) 
1.10 0.71 0.12 
Type 3 Tests of Fixed Effects 
Effect Fdf num, df den P 
Treatment assignment  F2,1951= 6.94 0.001 
Anxious depression status at baseline F1,1951=84.83 <0.0001 
Time F1,319=304.17 <0.0001 
Treatment assignment at baseline by 





Table 16: Odds ratios and 95% confidence intervals for the association between the 









Setraline vs placebo  1.17 0.69-1.97 0.39 
SJW vs placebo 0.90 0.53-1.54 0.45 
Melancholic depression status 
Nonmelancholic vs. melancholic 1.03 0.66-1.62 0.90 
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Table 17: Odds ratios and 95% confidence intervals for the association between the 









Sertraline vs placebo  1.16 0.69-1.97 0.39 
SJW vs placebo 0.90 0.53-1.53 0.45 
Anxious depression status 




Table 18: Clinical characteristics at week 8 of participants with melancholic versus 
nonmelancholic depression, by treatment response 
 





































































*Scores use LOCF except for SDS total score 
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Table 19: Clinical characteristics at week 8 of participants with anxious versus 
nonanxious depression by treatment response 
 









































































Table 20: Clinical characteristics at week 8 of participants with melancholic or nonmelancholic depression by treatment 
assignment and treatment response 
 
Melancholic Depression 
 St John’s Wort Placebo Sertraline 
Any response Yes No P Yes No p Yes No p 
Characteristic* 
HAM-D total 
























































































Table 20, continued: Clinical characteristics at week 8 of participants with melancholic or nonmelancholic depression by 




 St John’s Wort Placebo Setraline 
Any response Yes No p Yes No P Yes No p 
Characteristic* 
HAM-D total 


































































*Scores use LOCF except for SDS total score 
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 St John’s Wort Placebo Sertraline 
Any response Yes No p Yes No p Yes No p 
Characteristic*          
HAM-D total 
























































































Table 21, continued: Clinical characteristics at week 8 of participants with anxious or nonanxious depression by treatment 




 St John’s Wort Placebo Sertraline 
Any response Yes No p Yes No p Yes No p 
Characteristic*          
HAM-D total score, 
mean (SD) 











CGI-S score, mean 
(SD) 











CGI-I score, mean 
(SD) 











GAF total score, 
mean (SD) 











SDS total score, 
mean (SD) 


















Figure 1: Enrollment and outcomes during the Hypericum Trial6   
 
428 entered 1-week run-in phase 
 
340 randomized 
113 allocated to SJW 116 allocated to placebo 111 allocated to sertraline 
82 completed 8 
weeks of treatment 
31 withdrew 
84 completed 8 
weeks of treatment 
79 completed 8 
weeks of treatment 
32 withdrew 32 withdrew 
11 dropouts 
during first 2 
weeks 
5 dropouts 
during first 2 
weeks 
17 dropouts 
during first 2 
weeks 
88 not randomized: 
♦   32 no longer eligible 
♦   32 lost to follow-up 
♦   15 unknown reason  




Figure 2: Cumulative frequency distribution of modified Hamilton Endogenomorphy 

























Figure 3: Frequency distribution of modified Hamilton Endogenomorphy Subscale scores 






















Total HES melancholic depression score 
74 
 
Figure 4: Cumulative frequency distribution of HAM-D anxiety/somatization factor 




















Total score on HAM-D Anxiety/Somatization Factor 
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Figure 5: Frequency distribution of HAM-D anxiety/somatization factor scores at 
baseline in the Hypericum trial  
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